ArticleGastro hep advances2026
The Clinical Significance of Extrapancreatic Incidental Findings Detected During Pancreas Surveillance.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidental findings during pancreatic cyst surveillance: clinical relevance and implications for MRI protocol design.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Cancer screening tests have the potential to detect cancers and precancerous conditions, but one concern is the potential that screen-detected incidental findings lead to unnecessary, potentially harmful interventions. The aim of this study is to determine, the yield of extrapancreatic incidental findings that required management, including cancers, precancerous lesions, and other findings of diagnostic concern in patients undergoing pancreatic surveillance for their familial or genetic pancreatic cancer risk. Methods: We reviewed the pancreatic surveillance records of 925 patients enrolled in the Cancer of Pancreas Screening studies at The Johns Hopkins Hospital from 1998 to 2023 who had undergone at least one pancreatic surveillance test. Significant extra-pancreatic incidental findings that required diagnostic evaluation and/or treatment were tabulated, including the resulting diagnostic tests, therapeutic interventions, and complications. Results: The mean age/standard deviation at enrollment, of patients in the cohort was 58.0/10.4 years; 59.7% female), 220 (23.8%) had undergone baseline surveillance, 705 (76.2%) had undergone surveillance for a median of 4 years. Seventy-five extrapancreatic incidental findings were detected in 68 patients (7.3%), including 10 cancers, 80% of which were stage I and 8 (0.86%) precancerous lesions. Thirteen patients underwent surgical (n = 13), endoscopic (n = 9), or chemotherapy (n = 4). Twenty-five patients (2.7%) were recommended to undergo surveillance, (20 for nondysplastic Barrett's esophagus). Three patients (0.33%) were considered overtreated in retrospect (2 cholecystectomies, 1 partial nephrectomy, all laparoscopic). One patient had a postoperative complication treated successfully. Conclusion: Extrapancreatic incidental findings are commonly detected in patients undergoing pancreatic surveillance, but few signify serious pathology. Almost all interventions for incidental findings were for cancerous and precancerous lesions, with few instances of unnecessary interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.